Sept 1 (Reuters) – AstraZeneca said on Tuesday that a Chinese late-stage trial of a combination of its cancer drugs Tagrisso and Orpathys significantly improved progression-free survival when given as a first-line treatment for a type of lung cancer.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Mrigank Dhaniwala)
Comments